We are a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. We are developing a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells in patients or eliminate pathogenic autoreactive cells in patients with aut…
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (FY)
$0.00
▼ -100.0% YoY
Net Income (TTM)
-$165M
▲ +25.9% YoY
Op. Margin
–
ROIC
-34.50%
▲ +1.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$103M
▲ +25.6% YoY
Op. Cash Flow (TTM)
-$102M
▲ +25.5% YoY
Net Debt
-$254M
Net Cash Position
Cash & Equiv.
$333M
Continue Research
Peers
Biological Products, (No Diagnostic Substances) · Pick stocks to compare with ALLO
Held by ETFs
ALLO is in 22 US ETFs. The largest of them, with ALLO's weight in each:
Allogene Therapeutics (ALLO) in three numbers
Questions about Allogene Therapeutics
Is Allogene Therapeutics a high-quality business?
Allogene Therapeutics scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from SEC filings. Its best check is net debt at -$254M, and its weakest is return on capital at -34.5%. The Quality tab shows every check against its target.
Does Allogene Therapeutics (ALLO) pay a dividend?
No. Allogene Therapeutics (ALLO) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 10 Aug 2026 (period ending 30 Jun 2026), SEC. Price: last close 4 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in ALLO's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing ALLO
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.